Document is current
Any future updates will be listed below
-
Authors
Schairer, Catherine
Hablas, Ahmed
Eldein, Ibrahim AbdelBar Seif
Gaafar, Rabab
Rais, Henda
Mezlini, Amel
Ayed, Farhat Ben
Ayoub, Wided Ben
Benider, Abdellatif
Tahri, Ali
Khouchani, Mouna
Aboulazm, Dalia
Karkouri, Mehdi
Eissa, Saad
Bastawisy, Ahmed El
Yehia, Maha
Gadalla, Shahinaz M.
Swain, Sandra M.
Merajver, Sofia D.
Brown, Linda Morris
Pfeiffer, Ruth M. https://orcid.org/0000-0001-7791-2698
Soliman, Amr S.
-
Funding
Funding for this research was provided by:
National Institutes of Health (Grant R25 CA112383)
METAvivor (DK)
Breast Cancer Research Foundation (DK)
- License Information
-
More Information
Article History
Received: 24 December 2019
Accepted: 6 August 2020
First Online: 2 September 2020
Compliance with ethical standards
:
: Sandra Swain reports receiving honoraria from Novartis, personal fees from Cardinal Health, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, Genomic Health, Inivata, Peiris Pharmaceuticals, Tocagen; research support from Genentech; travel and accommodations from Caris Centers of Excellence, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, NanoString Technologies; and remuneration from AstraZeneca for participation on OlympiA IDMC. The other authors declare they have no conflicts of interest.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committees.
: Informed consent was obtained from all study participants.
